Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

PHASE4CompletedINTERVENTIONAL
Enrollment

702

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

March 30, 2020

Study Completion Date

September 9, 2021

Conditions
Vaccination
Interventions
BIOLOGICAL

Sabin-IPV and DTaP

simultaneously administration of Sabin-IPV and DTaP

BIOLOGICAL

Sabin-IPV

administration of Sabin-IPV only

BIOLOGICAL

DTaP

administration of DTaP only

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

collaborator

Jiangsu Province Center for Disease Control and Prevention

UNKNOWN

collaborator

Anhui Provincial Center for Disease Control and Prevention

UNKNOWN

collaborator

Sichuan Center for Disease Control and Prevention

OTHER_GOV

collaborator

Peking University

OTHER

collaborator

National Institutes for Food and Drug Control, China

OTHER

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04054882 - Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP | Biotech Hunter | Biotech Hunter